Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Should l Buy KRYS?
Source: Globenewswire
- Strong Financial Performance: Krystal Biotech anticipates Q4 2025 VYJUVEK net revenue between $106 million and $107 million, with full-year revenue expected between $388 million and $389 million, highlighting robust growth potential in the rare disease market.
- Clinical Pipeline Expansion: The company plans to accelerate clinical development for KB801 in 2026, increasing the enrollment target for its registrational study from 27 to 60 patients, aiming to expedite treatment for neurotrophic keratitis and solidify its market position in rare diseases.
- Clear Strategic Vision: Krystal Biotech aims to launch at least four rare disease medicines by the end of 2030, potentially benefiting over 10,000 patients, demonstrating its commitment and capability to address global treatment gaps in rare diseases.
- Ongoing R&D Investment: The company expects non-GAAP R&D and SG&A expenses to range from $175 million to $195 million in 2026, indicating a continued strategic investment in its clinical pipeline and larger indication projects to support long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 229.25 USD with a low forecast of 198.00 USD and a high forecast of 278.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 267.640
Low
198.00
Averages
229.25
High
278.00
Current: 267.640
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Krystal Biotech Rated as One of the Top Growth Stocks for the Next Decade
- Price Target Increase: Goldman Sachs analyst Andrea Tan raised Krystal Biotech's price target from $206 to $327, indicating a 16.7% upside from current levels, reflecting strong market confidence in its short-term growth potential.
- Strategic Program Development: The company is positioning itself for future growth with three registrational programs, KB801, KB803, and KB407, expected to support product launches around 2028, highlighting its strategic focus in the biotechnology sector.
- Investor Interest: Clear Street analyst William Maughan increased the price target from $288 to $338, offering a further 20.7% upside, emphasizing the sustained growth of Vyjuvek and the attractiveness of the company's expanding pipeline to investors.
- Neurotrophic Keratitis Market Potential: Analysts noted that KB801's potential in the neurotrophic keratitis market is a key focus for investors, with upcoming data releases expected to serve as significant catalysts for the stock's performance.
See More
Analysis of FBT Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: FBT's stock has a 52-week low of $141.375 and a high of $224.9399, with the last trade at $220.41, indicating its price is nearing the high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data
- Efficacy Data Update: ImmunityBio's updated efficacy and safety data from the QUILT-106 clinical study show that patients receiving CD19 CAR-NK therapy achieved 100% disease control over 15 months, significantly enhancing the company's competitive position in the Waldenström non-Hodgkin lymphoma space.
- Innovative Treatment Regimen: The study's use of CD19 CAR-NK cells combined with Roche's Rituxan allows outpatient treatment without chemotherapy, highlighting the therapy's strategic importance in terms of patient-friendliness and scalability.
- Strong Market Reaction: ImmunityBio's stock surged 106% over the past six months, significantly outpacing the industry's 22.1% growth, reflecting strong market confidence in its new therapy and positive investor sentiment.
- Future Development Plans: ImmunityBio aims to submit a biologics license application to the FDA by the end of 2026, with full enrollment in the QUILT-2.005 study expected to further bolster the company's market position in treating BCG-unresponsive bladder cancer.
See More
S&P 500 Futures Decline in Pre-Market Trading; Tempus AI and Klarna Group Take the Lead
Stock Market Opening: U.S. stock markets are set to open in two hours.
Tempus AI Inc. Performance: Tempus AI Inc. (TEM) saw a 12.4% increase in pre-market trading.
Klarna Group PLC Performance: Klarna Group PLC (KLAR) experienced a 6.6% rise in pre-market trading.
Market Sentiment: The pre-market gains indicate positive sentiment for both companies ahead of the market opening.
See More
Krystal Biotech Projects $389M Revenue for VYJUVEK in 2025
- Strong Financial Performance: Krystal Biotech anticipates fourth-quarter net product revenue for VYJUVEK to be between $106 million and $107 million, with full-year revenue projected at $388 million to $389 million, highlighting its market potential in rare disease therapies.
- Robust Cash Reserves: As of December 31, 2025, Krystal reported approximately $955 million in cash, cash equivalents, and investments, providing strong financial support for future R&D and market expansion initiatives.
- Clinical Trial Expansion: To expedite the development of KB801, Krystal has expanded enrollment in its ongoing registrational study from 27 to 60 patients, with top-line data expected before year-end 2026, demonstrating the company's proactive approach in rare disease drug development.
- Long-term Strategic Goals: Krystal aims to have at least four marketed rare disease medicines, including VYJUVEK, by 2030, reaching over 10,000 patients globally, reflecting its strong commitment to addressing the unmet needs of over 300 million people living with rare diseases worldwide.
See More
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025
- Strong Financial Performance: Krystal Biotech anticipates Q4 2025 VYJUVEK net revenue between $106 million and $107 million, with full-year revenue expected between $388 million and $389 million, highlighting robust growth potential in the rare disease market.
- Clinical Pipeline Expansion: The company plans to accelerate clinical development for KB801 in 2026, increasing the enrollment target for its registrational study from 27 to 60 patients, aiming to expedite treatment for neurotrophic keratitis and solidify its market position in rare diseases.
- Clear Strategic Vision: Krystal Biotech aims to launch at least four rare disease medicines by the end of 2030, potentially benefiting over 10,000 patients, demonstrating its commitment and capability to address global treatment gaps in rare diseases.
- Ongoing R&D Investment: The company expects non-GAAP R&D and SG&A expenses to range from $175 million to $195 million in 2026, indicating a continued strategic investment in its clinical pipeline and larger indication projects to support long-term growth.
See More
Krystal Biotech Rated as One of the Top Growth Stocks for the Next Decade
- Price Target Increase: Goldman Sachs analyst Andrea Tan raised Krystal Biotech's price target from $206 to $327, indicating a 16.7% upside from current levels, reflecting strong market confidence in its short-term growth potential.
- Strategic Program Development: The company is positioning itself for future growth with three registrational programs, KB801, KB803, and KB407, expected to support product launches around 2028, highlighting its strategic focus in the biotechnology sector.
- Investor Interest: Clear Street analyst William Maughan increased the price target from $288 to $338, offering a further 20.7% upside, emphasizing the sustained growth of Vyjuvek and the attractiveness of the company's expanding pipeline to investors.
- Neurotrophic Keratitis Market Potential: Analysts noted that KB801's potential in the neurotrophic keratitis market is a key focus for investors, with upcoming data releases expected to serve as significant catalysts for the stock's performance.
See More
Analysis of FBT Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: FBT's stock has a 52-week low of $141.375 and a high of $224.9399, with the last trade at $220.41, indicating its price is nearing the high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data
- Efficacy Data Update: ImmunityBio's updated efficacy and safety data from the QUILT-106 clinical study show that patients receiving CD19 CAR-NK therapy achieved 100% disease control over 15 months, significantly enhancing the company's competitive position in the Waldenström non-Hodgkin lymphoma space.
- Innovative Treatment Regimen: The study's use of CD19 CAR-NK cells combined with Roche's Rituxan allows outpatient treatment without chemotherapy, highlighting the therapy's strategic importance in terms of patient-friendliness and scalability.
- Strong Market Reaction: ImmunityBio's stock surged 106% over the past six months, significantly outpacing the industry's 22.1% growth, reflecting strong market confidence in its new therapy and positive investor sentiment.
- Future Development Plans: ImmunityBio aims to submit a biologics license application to the FDA by the end of 2026, with full enrollment in the QUILT-2.005 study expected to further bolster the company's market position in treating BCG-unresponsive bladder cancer.
See More
S&P 500 Futures Decline in Pre-Market Trading; Tempus AI and Klarna Group Take the Lead
Stock Market Opening: U.S. stock markets are set to open in two hours.
Tempus AI Inc. Performance: Tempus AI Inc. (TEM) saw a 12.4% increase in pre-market trading.
Klarna Group PLC Performance: Klarna Group PLC (KLAR) experienced a 6.6% rise in pre-market trading.
Market Sentiment: The pre-market gains indicate positive sentiment for both companies ahead of the market opening.
See More
Krystal Biotech Projects $389M Revenue for VYJUVEK in 2025
- Strong Financial Performance: Krystal Biotech anticipates fourth-quarter net product revenue for VYJUVEK to be between $106 million and $107 million, with full-year revenue projected at $388 million to $389 million, highlighting its market potential in rare disease therapies.
- Robust Cash Reserves: As of December 31, 2025, Krystal reported approximately $955 million in cash, cash equivalents, and investments, providing strong financial support for future R&D and market expansion initiatives.
- Clinical Trial Expansion: To expedite the development of KB801, Krystal has expanded enrollment in its ongoing registrational study from 27 to 60 patients, with top-line data expected before year-end 2026, demonstrating the company's proactive approach in rare disease drug development.
- Long-term Strategic Goals: Krystal aims to have at least four marketed rare disease medicines, including VYJUVEK, by 2030, reaching over 10,000 patients globally, reflecting its strong commitment to addressing the unmet needs of over 300 million people living with rare diseases worldwide.
See More
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025
- Strong Financial Performance: Krystal Biotech anticipates Q4 2025 VYJUVEK net revenue between $106 million and $107 million, with full-year revenue expected between $388 million and $389 million, highlighting robust growth potential in the rare disease market.
- Clinical Pipeline Expansion: The company plans to accelerate clinical development for KB801 in 2026, increasing the enrollment target for its registrational study from 27 to 60 patients, aiming to expedite treatment for neurotrophic keratitis and solidify its market position in rare diseases.
- Clear Strategic Vision: Krystal Biotech aims to launch at least four rare disease medicines by the end of 2030, potentially benefiting over 10,000 patients, demonstrating its commitment and capability to address global treatment gaps in rare diseases.
- Ongoing R&D Investment: The company expects non-GAAP R&D and SG&A expenses to range from $175 million to $195 million in 2026, indicating a continued strategic investment in its clinical pipeline and larger indication projects to support long-term growth.
See More
